

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM450469

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
NATIONAL BANK OF CANADA		11/08/2017	Corporation: CANADA

RECEIVING PARTY DATA

Name:	ATRIUM BIOTECH HOLDCO, INC.
Street Address:	490 Boston Post Road
City:	Sudbury
State/Country:	MASSACHUSETTS
Postal Code:	01776
Entity Type:	Corporation: DELAWARE
Name:	PURE ENCAPSULATIONS, INC.
Street Address:	490 Boston Post Road
City:	Sudbury
State/Country:	MASSACHUSETTS
Postal Code:	01776
Entity Type:	Corporation: DELAWARE
Name:	ATRIUM BIOTECH USA, INC.
Street Address:	490 Boston Post Road
City:	Sudbury
State/Country:	MASSACHUSETTS
Postal Code:	01776
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 18

Property Type	Number	Word Mark
Registration Number:	2096198	PURE ENCAPSULATIONS, INC.
Registration Number:	2396919	A.I. FORMULA
Registration Number:	2378633	A.P. FORMULA
Registration Number:	2302037	ULTRANUTRIENT
Registration Number:	2302038	NUTRIENT 950
Registration Number:	2430683	A.C. FORMULA
Registration Number:	2380503	ADR FORMULA

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	2304053	NUTRIENT 280 C
Registration Number:	2302042	MINERAL 650
Registration Number:	2304054	ISOPROTEIN PLUS
Registration Number:	2302043	VEINPRO
Registration Number:	2304055	PROSOOTHE
Registration Number:	2377586	NIACITOL
Registration Number:	2377587	IMM FORMULA
Registration Number:	2375292	CRANBERRY NS
Registration Number:	2375293	DGL PLUS
Registration Number:	2410417	+CAL+
Registration Number:	2468500	PUREWEIGH

CORRESPONDENCE DATA

Fax Number: 2127352000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212.735.5117 |

Email: francine.waldbaum@skadden.com

Correspondent Name: Skadden, Arps, Slate, Meagher & Flom LLP

Address Line 1: Four Times Square

Address Line 2: Francine Waldbaum

Address Line 4: New York, NEW YORK 10036

ATTORNEY DOCKET NUMBER:	099360/80
NAME OF SUBMITTER:	Cristina Vasile
SIGNATURE:	/Cristina Vasile/
DATE SIGNED:	11/10/2017

Total Attachments: 4

source=Aisle_NBC_TM_Release_3025_0920#page1.tif

source=Aisle_NBC_TM_Release_3025_0920#page2.tif

source=Aisle_NBC_TM_Release_3025_0920#page3.tif

source=Aisle_NBC_TM_Release_3025_0920#page4.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS, dated as of November 8th, 2017 (this "Release"), is made by NATIONAL BANK OF CANADA, a Canadian corporation, having a place of business at 1155 Metcalfe Street, 5th Floor, Montreal, Quebec H3B 4S9 as Administrative Agent and/or Creditor (in such capacity, together with any successor thereto in such capacity, the "Assignor"), in favor of ATRIUM BIOTECH HOLDCO, INC., a Delaware corporation, having a place of business at 490 Boston Post Road, Sudbury, Massachusetts 01776, PURE ENCAPSULATIONS, INC., a Delaware corporation, having a place of business at 490 Boston Post Road, Sudbury, Massachusetts 01776, and ATRIUM BIOTECH USA, INC., a Delaware corporation, having a place of business at 490 Boston Post Road, Sudbury, Massachusetts 01776 (the "Assignees"). All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement (as defined below).

WITNESSETH

WHEREAS, Atrium Biotechnologies Inc., a corporation organized under the laws of Canada that was the direct or indirect corporate parent of all the Assignees, and Assignor, amongst others, entered into a credit agreement dated as of January 17, 2005 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), pursuant to which the lenders thereunder agreed to grant credit to Atrium Biotechnologies Inc. from time to time, subject to the terms and conditions set forth therein;

WHEREAS, Assignees and Assignor entered into a U.S. security and pledge agreement dated as of January 17, 2005 (the "Security Agreement"), pursuant to which Assignees pledged, assigned and granted to Assignor for the benefit of the Creditors a first priority Lien upon and a continuing first priority security interest in all of Assignees' rights, title and interests in, to and under, amongst other things, all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, then existing or thereafter adopted or acquired by Assignees, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, or otherwise, and all renewals thereof, whether then owned or thereafter acquired and wherever located, and whether then existing or thereafter arising or created, including, without limitation, the trademarks and trademark applications listed in Schedule A hereto (collectively, the "Trademark Collateral");

WHEREAS, the Security Agreement was recorded with the United States Patent and Trademark Office on February 7, 2005 at Reel/Frame No. 3025/0920; and

WHEREAS, Assignor has agreed to release its Lien upon and continuing security interest in the Trademark Collateral and re-assign and transfer all of its right, title and interest in the Trademark Collateral to Assignees.


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby releases its Lien upon and

continuing security interest in all of the Trademark Collateral, and re-assigns and transfers any right, title and interest that Assignor may have in the Trademark Collateral to Assignees.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, Assignor has caused this Release to be duly executed and delivered by its duly authorized officer as of the date first written above.

NATIONAL BANK OF CANADA

By: 

Name: Dominic Albanese _____

Title: Managing Director _____

Per: 

Name: Bruno Lévesque _____

Title: Managing Director _____

**SCHEDULE A
TO
RELEASE OF SECURITY INTEREST
IN TRADEMARKS**

U.S. Trademark Registrations

Registered Owner	Jurisdiction	App. No.	Reg. No.	Mark
Pure Encapsulations, Inc.	United States	74/222647	2096198	PURE ENCAPSULATIONS, INC. (DESIGN)
Pure Encapsulations, Inc.	United States	75/574050	2396919	A.I. FORMULA
Pure Encapsulations, Inc.	United States	75/574051	2378633	A.P. FORMULA
Pure Encapsulations, Inc.	United States	75/574052	2302037	ULTRANUTRIENT
Pure Encapsulations, Inc.	United States	75/574053	2302038	NUTRIENT 950
Pure Encapsulations, Inc.	United States	75/574054	2430683	A.C. FORMULA
Pure Encapsulations, Inc.	United States	75/574222	2380503	ADR FORMULA
Pure Encapsulations, Inc.	United States	75574266	2304053	NUTRIENT 280 C
Pure Encapsulations, Inc.	United States	75/574267	2302042	MINERAL 650
Pure Encapsulations, Inc.	United States	75574269	2304054	ISOPROTEIN PLUS
Pure Encapsulations, Inc.	United States	75574270	2302043	VEINPRO
Pure Encapsulations, Inc.	United States	75574271	2304055	PROSOOTHE
Pure Encapsulations, Inc.	United States	75/804576	2377586	NIACITOL
Pure Encapsulations, Inc.	United States	75/804577	2377587	IMM FORMULA
Pure Encapsulations, Inc.	United States	75/804578	2375292	CRANBERRY NS
Pure Encapsulations, Inc.	United States	75/804579	2375293	DGL PLUS
Pure Encapsulations, Inc.	United States	75/804580	2410417	+CAL+
Pure Encapsulations, Inc.	United States	75/864733	2468500	PUREWEIGH